{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:38:10Z","timestamp":1763728690421,"version":"3.37.3"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","award":["111833"],"award-info":[{"award-number":["111833"]}],"id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Both germline and somatic BReast CAncer gene (BRCA) mutations are poor prognostic markers in men with localized or metastatic prostate cancer. For instance, men with these mutations often are diagnosed with prostate cancer earlier and develop metastatic disease earlier compared with those who do not harbor similar mutations. Patients with germline alterations typically have more advanced disease and shorter overall survival (Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-1757. doi:10.1200\/JCO.2012.43.1882). The risk of disease progression to metastatic disease is significant in patients with this genotype of prostate cancer. The percentage of patients free from metastatic disease was 90%, 72%, and 50%, respectively, compared with 97%, 94%, and 84% at 3, 5, and 10 years for patients with intact DNA repair (P\u2005&lt;\u2005.001) (Castro E, Goh C, Leongamornlert D, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol. 2015;68(2):186-193. doi: 10.1016\/j.eururo.2014.10.022). DNA damage repair non-BRCA mutations include alterations in genes such as ATM, CHEK2, PALB2, and RAD51. While less common than BRCA mutations, they have emerged as significant prognostic markers in prostate cancer. These BRCAness mutations are associated with a higher risk of aggressive disease and poorer survival outcomes. Given the debilitating physical and psychological side effects of androgen deprivation therapy (ADT) in relatively younger men with prostate cancer, delaying ADT in these men may be an attractive strategy. Given the proven efficacy of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors in the castration-resistant prostate cancersetting, PARP inhibitor monotherapy in a nonmetastatic castration-sensitive (nmCSPC) setting has the potential to delay metastasis and delay the onset of ADT related symptoms.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This is a single-arm, single-center, open-label, phase II trial to assess the efficacy of rucaparib in patients with high-risk biochemically recurrent (BCR) nmHSPC, which was defined as PSA doubling time of &lt;9 months, demonstrating a \u201cBRCAness\u201d genotype (BRCA1\/2 and other homologous recombination repair mutations). A total of 15 patients were intended to be enrolled, with an expected enrollment duration of 12 months. Patients were given rucaparib 600 mg orally twice daily and were allowed to remain on study treatment until PSA progression defined by Prostate Cancer Working Group 3, with 2 years of follow-up after study treatment. We anticipated a total of 2-3 years until completion of the clinical trial. The primary endpoint was to assess the PSA progression-free survival (PSA-PFS). The secondary endpoints of the study were safety, the proportion of patients with a PSA 50% response (PSA 50), and an undetectable PSA. A 4-week treatment duration comprised one cycle.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The study started enrolling in June 2019 and was prematurely terminated in June 2022 after the accrual of 7 patients because of changing standard of care treatments with the introduction of next-generation scans, eg, prostate-specific membrane antigen positron emission tomography (PSMA-PET). Seven patients were enrolled in the study with the following pathogenic alterations: ATM (n\u2005=\u20053), BRCA2 (n\u2005=\u20052), BRCA1 (n\u2005=\u20051), BRIP1 (n\u2005=\u20051), and RAD51 (n\u2005=\u20051). The median duration of follow-up was 18 months. A median of 20 cycles (range 4-42) was completed, median PSA-PFS was 35.37 months (95% CI, 0-85.11 months). In total, 2 patients achieved PSA50; both also achieved nadir PSA as undetectable. Grade\u2005\u2265\u20053 adverse events (AEs) were anemia and rash (in 1 patient each). No dose-limiting toxicities or severe AEs were seen.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Rucaparib demonstrated acceptable toxicity and efficacy signal as an ADT-sparing approach in patients with biochemically recurrent nonmetastatic prostate cancer. It is currently challenging to understand the optimal value of systemic therapy in this disease setting due to the rapidly changing standard of care. Additionally, there are relatively few patients with BRCAness who present with nonmetastatic hormone-sensitive prostate cancer (ClinicalTrials.gov Identifier: NCT03533946).<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae030","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:48:35Z","timestamp":1709837315000},"page":"450-e725","source":"Crossref","is-referenced-by-count":5,"title":["A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating \u201cBRCAness\u201d Genotype (ROAR)"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0382-6882","authenticated-orcid":false,"given":"Kamal Kant","family":"Sahu","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center , Westwood, KS , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Mathew Thomas","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallory","family":"Benson","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-6614","authenticated-orcid":false,"given":"Manish","family":"Kohli","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin L","family":"Maughan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2024050313101761700_CIT0001","first-page":"719","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume-title":"N Engl J Med","author":"Fizazi","year":"2023"},{"key":"2024050313101761700_CIT0002","first-page":"2345","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume-title":"N Engl J Med","author":"Hussain","year":"2020"},{"key":"2024050313101761700_CIT0003","first-page":"1697","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume-title":"N Engl J Med","author":"Mateo","year":"2015"},{"issue":"6_suppl","key":"2024050313101761700_CIT0004","doi-asserted-by":"crossref","first-page":"TPS221","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS221","article-title":"Talapro-3: a phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)","volume":"40","author":"Agarwal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024050313101761700_CIT0005","first-page":"388","article-title":"Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy","volume-title":"Clin Endocrinol (Oxf)","author":"Cheung","year":"2017"},{"key":"2024050313101761700_CIT0006","first-page":"837","article-title":"Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP","volume-title":"J Clin Oncol","author":"Stockler","year":"2022"},{"key":"2024050313101761700_CIT0007","first-page":"825","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial","volume-title":"J Clin Oncol","author":"Rush","year":"2022"},{"key":"2024050313101761700_CIT0008","first-page":"914","article-title":"Apalutamide plus androgen deprivation therapy for metastatic castration-sensitive prostate cancer: analysis of pain and fatigue in the phase 3 TITAN study","volume-title":"J Urol","author":"Agarwal","year":"2021"},{"key":"2024050313101761700_CIT0009","first-page":"958","article-title":"Health-related quality of life at the SPARTAN final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy","volume-title":"Eur Urol Focus","author":"Oudard","year":"2022"},{"key":"2024050313101761700_CIT0010","first-page":"138","article-title":"Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial","volume-title":"Eur J Cancer","author":"Smith","year":"2021"},{"key":"2024050313101761700_CIT0011","first-page":"393","article-title":"Pain and health-related quality of life with olaparib versus physician\u2019s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial","volume-title":"Lancet Oncol","author":"Thiery-Vuillemin","year":"2022"},{"key":"2024050313101761700_CIT0012","first-page":"1402","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume-title":"J Clin Oncol","author":"Scher","year":"2016"},{"key":"2024050313101761700_CIT0013","first-page":"17","article-title":"Cancer statistics, 2023","volume-title":"CA Cancer J Clin","author":"Siegel","year":"2023"},{"key":"2024050313101761700_CIT0014","first-page":"e241","article-title":"Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions","volume-title":"Am Soc Clin Oncol Educ Book","author":"McKay","year":"2020"},{"key":"2024050313101761700_CIT0015","first-page":"1748","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume-title":"J Clin Oncol","author":"Castro","year":"2013"},{"key":"2024050313101761700_CIT0016","first-page":"186","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume-title":"Eur Urol","author":"Castro","year":"2015"},{"key":"2024050313101761700_CIT0017","first-page":"1949","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume-title":"Lancet","author":"Coleman","year":"2017"},{"issue":"16_suppl","key":"2024050313101761700_CIT0018","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1200\/JCO.2023.41.16_suppl.5087","article-title":"Phase 2 study of olaparib (without ADT) in men with biochemically recurrent prostate cancer (BCR) after prostatectomy","volume":"41","author":"Marshall","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024050313101761700_CIT0019","first-page":"737","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume-title":"N Engl J Med","author":"Sweeney","year":"2015"},{"key":"2024050313101761700_CIT0020","first-page":"727","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume-title":"Lancet Oncol","author":"Duchesne","year":"2016"},{"key":"2024050313101761700_CIT0021","first-page":"453","article-title":"Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer","volume-title":"JAMA Oncol","author":"Hershman","year":"2016"},{"key":"2024050313101761700_CIT0022","first-page":"291","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume-title":"Lancet","author":"Agarwal","year":"2023"},{"key":"2024050313101761700_CIT0023","first-page":"103","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume-title":"Lancet","author":"Bolla","year":"2002"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/450\/57396312\/oyae030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/29\/5\/450\/57396312\/oyae030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T13:10:48Z","timestamp":1714741848000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/29\/5\/450\/7623988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae030","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,3,7]]}}}